Primary Peritoneal Mesothelioma (PPM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Primary Peritoneal Mesothelioma (PPM) Market Outlook

Thelansis’s “Primary Peritoneal Mesothelioma (PPM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Peritoneal Mesothelioma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Primary Peritoneal Mesothelioma (PPM) Overview

Primary Peritoneal Mesothelioma (PPM) is an uncommon and swiftly progressive neoplasm originating from the mesothelial cells lining the peritoneum and spreads extensively within the confines of the abdominal cavity. The leading cause of peritoneal mesothelioma is asbestos exposure. Asbestos is a group of minerals that can cause cancer when inhaled or ingested. People who have worked in industries that use asbestos, such as shipbuilding, construction, and manufacturing, are at increased risk of developing peritoneal mesothelioma. Other risk factors for peritoneal mesothelioma include:

1. Exposure to radiation
2. Exposure to certain chemicals, such as vinyl chloride
3. Family history of mesothelioma
4. Certain genetic mutations

The symptoms of peritoneal mesothelioma can vary depending on the cancer stage. Early symptoms may include Abdominal pain, Abdominal swelling, Weight loss, Nausea, Vomiting, Constipation, Indigestion, and Fatigue. The prognosis for patients with peritoneal mesothelioma is poor. The average survival rate for patients with this type of cancer is 12 to 18 months. However, survival rates can vary depending on the cancer stage, the patient's age and overall health, and the type of treatment they receive.

• Only 10–15% of the approximately 3,300 cases of mesothelioma diagnosed in the USA yearly are peritoneal, resulting in about 600 new cases annually.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: